Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (March 2021)

30 slides from Aerie Pharmaceuticals's investor presentation, Mar 17, 2021

  1. Slide 1: Company Overview Investor Presentation March 2021

    Slide 1: Company Overview Investor Presentation March 2021

    Company Overview Investor Presentation March 2021 Exhibit 99.1

  2. Slide 2: Important Information

    Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: Aerie Overview

    Slide 3: Aerie Overview

    Aerie Overview Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. AR-15512, AR-1105, AR-13503 and AR-14034 are development stage product candidates and are not approved by any regulatory agency. Dex: Dexamethasone Aerie IOP–Reducing Products (IP

  4. Slide 4: Aerie Overview: 2020 U.S. Glaucoma Market

    Slide 4: Aerie Overview: 2020 U.S. Glaucoma Market

    Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Estimated Glaucoma Market TRx Mix Medicare Part D & Medicaid, 59% Commercial & Cash, 30% Graph Source: IQVIA 2020 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker - ~$3B Market, 34M TRx, 55M bottles - 55% of

  5. Slide 5: Glaucoma Commercialization Focus

    Slide 5: Glaucoma Commercialization Focus

    Glaucoma Commercialization Focus Ongoing communication of the MOST Data and coverage via various communication channels Rhopressa® Coverage: 90% Commercial, 89% Med D Rocklatan® Coverage: 89% Commercial, 56% Med D plus 15% Low Income Subsidy Continued execution of the Pulse Strategy, focused on driv

  6. Slide 6: Focused on "Pull-Through" to Gain Share

    Slide 6: Focused on "Pull-Through" to Gain Share

    Focused on “Pull-Through” to Gain Share: Example from 05/01/20 Med D Coverage Win Humana Part D Effective May 1, 2020 PA to PB (eST) Apr 2020¹ Dec 2020 National Market Share (Part D) Aerie Franchise 1.9% 2.3% New Payer Part D Market Share Aerie Franchise 1.1% Difference vs National MS (-0.8%) 2.0% D

  7. Slide 7: U.S. Glaucoma Franchise Update

    Slide 7: U.S. Glaucoma Franchise Update

    For Investor Use U.S. Glaucoma Franchise Update Rhopressa® and Rocklatan® have not been approved by any regulatory authority other than the FDA and EMA. Actual Weekly Sales-Out to Pharmacies Data as of 3/5/2021 IQVIA Weekly Data as of 3/5/2021 IQVIA reporting for all reported industry products chang

  8. Slide 8: Advancing the Pipeline

    Slide 8: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement AR-14034 Imp

  9. Slide 9: U.S. Dry Eye Market: Under-diagnosed and Under-treated

    Slide 9: U.S. Dry Eye Market: Under-diagnosed and Under-treated

    For Investor Use U.S. Dry Eye Market: Under-diagnosed and Under-treated Estimated 30 million dry eye sufferers in the United States; less than 3 million treated Dry eye related symptoms are one of the most common reasons for patients to visit an eye care professional Represents a significant health

  10. Slide 10: AR-15512 for Dry Eye: Novel Mechanism of Action

    Slide 10: AR-15512 for Dry Eye: Novel Mechanism of Action

    AR-15512 for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors Topical eye drop TRPM8 receptor is a cold thermoreceptor ion channel located on corneal nerve endings Reduced corneal temperature triggered by tear evaporation activates TRPM8 which leads to: Increased basal tear

  11. Slide 11: AR-15512 (TRPM8 Agonist) for Dry Eye: How AR-15512 works

    Slide 11: AR-15512 (TRPM8 Agonist) for Dry Eye: How AR-15512 works

    AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

  12. Slide 12: AR-15512 for Dry Eye: Phase 2a Study

    Slide 12: AR-15512 for Dry Eye: Phase 2a Study

    AR-15512 for Dry Eye Avizorex completed a Phase 2a study in early 2019 in 109 subjects One concentration (0.0014%) and two dosing regimens (BID/TID) for 4 weeks were evaluated Primary endpoint: % of patients ≥ 20 points change in symptoms questionnaire (SANDE) Secondary endpoints: Schirmer’s test (t

  13. Slide 13: Significant efficacy for sign and symptoms with BID dosing

    Slide 13: Significant efficacy for sign and symptoms with BID dosing

    Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days For Investor Use ++Data on File Symptoms: SANDE Score Percentage of patients improving ≥20 score p=0.1 p=0.021 Graph on the right represents primary endpoint with a subset of more se

  14. Slide 14: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights: Schirmer

    Slide 14: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights: Schirmer

    ++Data on File For Investor Use AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days

  15. Slide 15: Dry Eye Program: AR-15512

    Slide 15: Dry Eye Program: AR-15512

    For Investor Use Dry Eye Program: AR-15512 Target symptoms: significant step in addressing the symptoms of dry eye patients and providing a cooling sensation Impact basal tear production: production of natural tears and not just an acute reflex tear Safe for long-term use Other approved products on

  16. Slide 16: AR-15512: COMET-1 Phase 2b Underway

    Slide 16: AR-15512: COMET-1 Phase 2b Underway

    For Investor Use AR-15512: COMET-1 Phase 2b Underway Clinical Trial Series named “COMET” = Cold Thermoreceptor Modulation as an Effective Treatment Phase 2b clinical study commenced October 2020 Phase 2b study is evaluating efficacy and safety of 0.0014% and 0.003% BID 360 patients (1:1:1) for 3 mon

  17. Slide 17: 2019 U.S. Retinal Disease Market

    Slide 17: 2019 U.S. Retinal Disease Market

    For Investor Use 2019 U.S. Retinal Disease Market: Need for Reduced Injection Frequency, New MOAs Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 Frequent intravitreal injections required to maintain vision gains Represents a significant burden for patients and p

  18. Slide 18: Aerie's Proprietary Drug Delivery Platform for Retinal Disease

    Slide 18: Aerie's Proprietary Drug Delivery Platform for Retinal Disease

    For Investor Use Aerie’s Proprietary Drug Delivery Platform for Retinal Disease – Predictable and Flexible Customizable drug elution, reproducible manufacturing Proprietary bio-erodible formulations, PRINT ® manufacturing Longer treatment duration, reduced injection frequency Enables once or twice p

  19. Slide 19: Aerie's Proprietary Drug Delivery Technology

    Slide 19: Aerie's Proprietary Drug Delivery Technology

    For Investor Use Aerie’s Proprietary Drug Delivery Technology: A Platform for Future Innovation Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg wAMD DME RVO Dry AMD/GA Glaucoma Othe

  20. Slide 20: AR-1105 (Dexamethasone) Implant

    Slide 20: AR-1105 (Dexamethasone) Implant

    AR-1105 (Dexamethasone) Implant Positive Topline Phase 2 results in RVO Phase 3 plans underway for the U.S. and Europe for DME Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administration due to smaller needle Potential for fewer ad

  21. Slide 21: AR-1105 Implant: Phase 2 Topline Summary

    Slide 21: AR-1105 Implant: Phase 2 Topline Summary

    AR-1105 (Dexamethasone) Implant: Phase 2 Topline Summary The Phase 2 clinical trial (AR-1105-CS201) was conducted at 19 centers in the United States. The objective was to evaluate two clinical formulations of AR-1105, CF-1 and CF-2 (each containing 340 µg dexamethasone), with different release profi

  22. Slide 22: AR-1105 Opportunity

    Slide 22: AR-1105 Opportunity

    AR-1105 Opportunity The DME market is growing in the United States and abroad The 6-month sustained efficacy of AR-1105 in the P2 study may render this product, if approved, highly competitive in both the U.S. and European markets AR-1105 may be viewed as a more favorable treatment alternative for a

  23. Slide 23: AR-14034 (Axitinib) Implant Opportunity

    Slide 23: AR-14034 (Axitinib) Implant Opportunity

    AR-14034 (Axitinib) Implant Opportunity 1. Market Scope Estimates 2020; http://market-scope.com/ Aflibercept Ranibizumab Bevacizumab Brolucizumab Axitinib For Investor Use 2019 IVT anti-VEGF worldwide market $13B; est. $22B by 20251 Current anti-VEGF pipeline dominated by longer duration products ta

  24. Slide 24: Axitinib Is Preferred Small Molecule for VEGF Inhibition

    Slide 24: Axitinib Is Preferred Small Molecule for VEGF Inhibition

    Axitinib Is Preferred Small Molecule for VEGF Inhibition Pan-VEGF receptor inhibitor (inhibits all isoforms of VEGF-R) Approved for systemic use in 2012 for the treatment of renal cell carcinoma Higher potency and less off-target activity than other small molecule inhibitors Most selective For Inves

  25. Slide 25: Axitinib Implant: Results Support Up to 12 Months Duration

    Slide 25: Axitinib Implant: Results Support Up to 12 Months Duration

    Axitinib Implant: Results Support Up to 12 Months Duration in Clinic Proprietary polymer blend produces optimal drug elution profile Maintains high elution rate over time Drug release rate in rabbits predicts up to 12-months duration (once a year injection) in clinic Aerie rabbit data accurately pre

  26. Slide 26: Expanding Aerie Franchise: Japan

    Slide 26: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful topline results released in November 2019 First Phase 3 trial commenced in Japan in December 2020 Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2020. *TRx calculated from IQVIA unit data (1 month =

  27. Slide 27: AR-13324-CS208 Japan Phase 2 Study Topline Results

    Slide 27: AR-13324-CS208 Japan Phase 2 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

  28. Slide 28: AR-13324-CS208 Japan Phase 2 Study Topline Results: IOP

    Slide 28: AR-13324-CS208 Japan Phase 2 Study Topline Results: IOP

    P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation AR-13324-CS208 Japan Phase 2 Study Topline Results For Investor Use

  29. Slide 29: Expanding Aerie Franchise: Europe

    Slide 29: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019 and for Roclanda® (Rocklatan®) in January 2021 Mercury 3: Reported successful 90-day topline data in September 2020; Rocklatan® (known as Roclanda® in Europe) achieved non-

  30. Slide 30: Summary: Key Priorities

    Slide 30: Summary: Key Priorities

    For Investor Use Summary Key Priorities Driving continued Rhopressa® and Rocklatan® volume growth in the U.S. Globalization Strategy Japan: Santen collaboration commencing and first Phase 3 trial underway Europe: Significant interest from potential collaborators Ireland Manufacturing Facility approv

Source: SEC EDGAR · 8-K filed Mar 17, 2021

More decks from Aerie Pharmaceuticals Inc.